C4 Therapeutics, Inc. (CCCC)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 41/100 (MEDIUM), 22.5 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 50.72% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
- C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting
- C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates
- C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know
- C4 Therapeutics Reports 53% Response Rate for Cemsidomide at RP2D
- C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?
- C4 Therapeutics to Participate in Upcoming Conferences
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for C4 Therapeutics, Inc..
Full CCCC Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.